Self-Oxygenated Radionuclide Delivery System for Synergistic Sensitization of Tumor Chemotherapy and Radionuclide Therapy

Radionuclide therapy is a clinically effective approach for precision cancer treatment. However, its efficacy is severely compromised by the hypoxic tumor microenvironment and intrinsic DNA self-repair mechanisms. Moreover, a single treatment modality is often insufficient to eradicate tumors. To address these challenges, we designed and constructed a multifunctional dendritic mesoporous silica (dendritic mesoporous silica nanoparticles)-based delivery system co-loaded with the chemotherapeutic agent 5-fluorouracil (5-FU) and catalase (CAT). The delivery system surface was modified with human serum albumin and hyaluronic acid (HA), followed by radiolabeling with the radionuclide 131I to enable tumor-targeted delivery, hypoxia alleviation, and synergistic radiotherapy−chemotherapy effects. This radionuclide delivery system exhibits excellent radiolabeling stability, biocompatibility, and SPECT imaging properties. It leverages CAT to efficiently catalyze the decomposition of endogenous H2O2 in the tumor microenvironment to generate O2, thereby significantly relieving tumor hypoxia. HA modification confers superior active tumor-targeting capability, while sustained release of 5-FU under acidic conditions at the tumor site effectively inhibits DNA replication. Both in vitro and in vivo experiments demonstrate that this system synergistically enhances the efficacy of 131I brachytherapy and 5-FU chemotherapy, leading to marked tumor growth inhibition with low systemic toxicity. Overall, this study overcomes the hypoxic tumor barrier and achieves synergistic targeted therapy combined with chemoradiotherapy, offering a novel strategy for effective and low-toxicity clinical treatment of solid tumors.

Authors

Institutions

Publication Details

Journal
Molecular Pharmaceutics
Published
2026-11-18
DOI
https://doi.org/10.1021/acs.molpharmaceut.6c01178
Primary Topic
Nanoplatforms for cancer theranostics
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Self-Oxygenated Radionuclide Delivery System for Synergistic Sensitization of Tumor Chemotherapy and Radionuclide Therapy

Zhifang Wu, Yan Cheng, Sijin Li, Hua Wei et al.
5 links
Molecular Pharmaceutics
Nanoplatforms for cancer theranostics
article

Self-Oxygenated Radionuclide Delivery System for Synergistic Sensitization of Tumor Chemotherapy and Radionuclide Therapy

Zhifang Wu, Yan Cheng, Sijin Li, Hua Wei, Junping Lv, Haitao Zhou, Yaqiong Zhang, Xirong Li, LeiLei Huang, Menghua Yin, Hongwei Qu, Yan Wang, Jie An, Min Li, Chenliang Niu, Qianwen He, Yingfang Song
article en

Abstract

Radionuclide therapy is a clinically effective approach for precision cancer treatment. However, its efficacy is severely compromised by the hypoxic tumor microenvironment and intrinsic DNA self-repair mechanisms. Moreover, a single treatment modality is often insufficient to eradicate tumors. To address these challenges, we designed and constructed a multifunctional dendritic mesoporous silica (dendritic mesoporous silica nanoparticles)-based delivery system co-loaded with the chemotherapeutic agent 5-fluorouracil (5-FU) and catalase (CAT). The delivery system surface was modified with human serum albumin and hyaluronic acid (HA), followed by radiolabeling with the radionuclide 131I to enable tumor-targeted delivery, hypoxia alleviation, and synergistic radiotherapy−chemotherapy effects. This radionuclide delivery system exhibits excellent radiolabeling stability, biocompatibility, and SPECT imaging properties. It leverages CAT to efficiently catalyze the decomposition of endogenous H2O2 in the tumor microenvironment to generate O2, thereby significantly relieving tumor hypoxia. HA modification confers superior active tumor-targeting capability, while sustained release of 5-FU under acidic conditions at the tumor site effectively inhibits DNA replication. Both in vitro and in vivo experiments demonstrate that this system synergistically enhances the efficacy of 131I brachytherapy and 5-FU chemotherapy, leading to marked tumor growth inhibition with low systemic toxicity. Overall, this study overcomes the hypoxic tumor barrier and achieves synergistic targeted therapy combined with chemoradiotherapy, offering a novel strategy for effective and low-toxicity clinical treatment of solid tumors.

Molecular Pharmaceutics
Shanxi Medical University (CN), Shanxi University (CN)
National Natural Science Foundation of China, Natural Science Foundation for Young Scientists of Shanxi Province
Good health and well-being
Nanoplatforms for cancer theranostics
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon